Takeda has voluntarily withdrawn its U.S. Biologics License Application for Dengue vaccine candidate Tak-003, according to Reuters.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TAK:
- Takeda, F-star enter strategic collaboration, license agreement
- Takeda presents interim results from pivotal Phase 3 trial for TAK-755
- Arrowhead presents updated data from Phase 2 SEQUOIA study
- Takeda presents data from HYQVIA investigation as maintenance therapy for CIDP
- Hutchmed, Takeda publish phase 3 results of Fresco-2 trial in The Lancet